Αρχική World News Conducting Phase I Clinical Trials During the COVID-19 Pandemic

Conducting Phase I Clinical Trials During the COVID-19 Pandemic

In a perspective article published on 27 July 2020 in the European Journal of Cancer, Dr Sophie Postel-Vinay and colleagues of the Drug Development Department (DITEP), Gustave Roussy in Villejuif, France discuss the key factors to be considered in conducting the phase I clinical trials during the COVID-19 pandemic, as well as in the management of COVID-19-positive cancer patients who are enrolled in those trials. In particular, the authors present the risks and challenges in COVID-19-positive cancer patients enrolled in the phase I clinical trials from the aspects of safety, toxicity causality assessment, drug efficacy evaluation and clinical research priorities. They proposed the guidelines for conducting phase I clinical trials and management of COVID-19 positive cancer patients during the pandemic.

The authors wrote in the background that cancer is associated with a higher probability of severe forms of COVID-19. Phase I clinical trials trials require an intensive monitoring of patients with multiple in-patient and out-patient unit visits which may represent an additional risk factor for SARS-CoV-2 infection. The occupancy of intensive care units (ICUs) by COVID-19 patients is a significant additional factor to consider when enrolling cancer patients in phase I clinical trials due to frequent life-threatening complications, such as cytokine release syndrome (CRS) in trials evaluating CAR-T cells or bispecific antibodies or in those undergoing complicating tumour biopsies.

Currently, there are no recommendations for the management of COVID-19-positive cancer patients included in phase I clinical trials. The authors wrote that their reflections are based on their experience only. The phase I drug safety profile should be considered in the decision of maintaining a COVID-19 positive patient in the trial. The investigational drug should be temporarily or permanently halted in case of any doubt of increased safety risk.

The authors suggested that any candidate for phase I clinical trial should be screened for SARS-CoV-2 by using PCR prior starting the experimental treatment. The patients with a positive PCR should be excluded from the clinical trial, even if asymptomatic at the time of diagnosis. Furthermore, they recommended screening weekly for SARS-CoV-2 by PCR during the dose limiting toxicity (DLT) period and replacing patients who develop a clinical or biological (e.g. asymptomatic but PCR positive) SARS-CoV-2 infection during the DLT period. Beyond the screening phase and the DLT period, they suggested to perform a regular SARS-CoV-2 PCR at the end of the DLT period and subsequently every four cycles and/or upon clinical symptoms. Patients who develop COVID-19 after the DLT period or during the dose-expansion phase may stay in the trial, as long as the treatments received for the management of the COVID-19 do not interfere with the phase I drug metabolism or efficacy.

In terms of clinical research priorities, the authors wrote that from a regulatory point of view and by law, a patient cannot be included in two different therapeutic interventional trials. However, inclusion in a study evaluating treatments against COVID-19 should probably be favoured at current time.

The authors wrote that in case of an asymptomatic or non-severe COVID-19 confirmed in a patient included in the phase I trial outside the DLT period, the patient could stay in the trial in most cases. However, adjustments should be done whenever feasible until the patient has recovered clinically and biologically, after discussion and approval of the trial sponsor, including minor deviations in order to limit hospital visits, teleconsulting at increased frequency with the phase I investigator, combined with regular home visits from the patient’s local general practitioner and blood tests at a local facility, treatment shipping to the patient’s domicile, skipping of some surveillance clinics at the hospital when the patient has been stable and on trial for more than 6 months and does not present any evolving drug-related adverse event, stronger personal protection for the patient, active and regular reminder to strictly avoid any self-medication and over the counter drugs. In order to limit the risk of COVID-19 in cancer patients included in phase I clinical trial, the patient and its household should also be regularly reminded of strictly respect the self-protection measures.

The Gustave Roussy experience

The authors wrote that COVID-19 was intense in the Paris region from mid March to end of April 2020. From 14th March to 28th April 2020, 178 cancer patients were managed for COVID-19 at the Gustave Roussy. In total, 125 patients (70.2%) were hospitalised for COVID-19, 47 patients (26.4%) developed clinical worsening and 31 patients (17.4%) died.

During that period, the DITEP continued its activity but all lung biopsies were cancelled to limit the risk of severe complications such as pneumothorax that would require access to the ICU, all patients were tested at least at Cycle 1 Day 1 using rapid PCR, visits to the hospital were cancelled whenever feasible and teleconsultation was favoured as well as treatment shipment at home.

The patients were managed according to next principles:

  • In case of asymptomatic patients with both COVID-19 PCR and serology negative statuses, or PCR negative but serology positive status, social distancing and mask was recommended;
  • In case of asymptomatic patients with COVID-19 PCR positive, but serology negative status, delay in unnecessary visit and treatment was recommended;
  • In case of symptomatic patients with COVID-19 PCR positive and serology negative status, delay or stop of participation in phase I clinical trial was recommended.

The authors reported that 3 patients who received bispecific agents and developed a cytokine release syndrome were successfully managed in their ward with strong interaction with the Gustave Roussy intensive care unit.

Rapid PCR tests identified 4 patients with a COVID 19-positive PCR: one patient in screening, for which Cycle 1 Day 1 was delayed; one patient in the DLT period, who was maintained in the trial as he remained completely asymptomatic and did not develop any adverse event; and two patients at later stages of the phase I clinical trial (cycles 10 and 12) who required a treatment delay because of self-isolation. No COVID-19-related death occurred.

Phase I clinical trials are the most resource-consuming and complicated form of clinical trials, from a safety and organisational point of view, as they involve multiple hospital teams (clinical trial unit, pharmacy, interventional radiology, etc.), clinical research organisations and drug companies, and require intensive patient monitoring. The authors concluded that during the peak of the pandemic in France, they successfully managed to maintain their drug development unit open and to treat patients without any, while not causing any nosocomial COVID-19 infection.

The authors also suggested creation of an international registry and Task Force for phase I cancer patients with COVID-19, so that various practices can be compared and eventually the consensus guidelines to be established.


Postel-Vinay S, Massard C, Soria J-CS. COVID-19 outbreak and Phase 1 trials: should we consider a specific patient management? European Journal of Cancer; Published online on 27 July 2020. DOI: https://doi.org/10.1016/j.ejca.2020.07.009



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Dad Creates Inclusive Children’s Book For Daughter With Disability And Others Like Her

Danny Jordan is a television producer and father of a child with an upper limb difference. Since there aren’t many children’s books out there...

Atlantic rowing trio smash world record and raise thousands for cancer charities

Abby, Charlotte and Kat (left to right) in English Harbour after breaking the world record. Three British women, including one with an incurable cancer, have...

Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer

A global artificial intelligence (AI) competition, the Prostate cANcer graDe Assessment (PANDA) challenge, compiled and publicly released a European cohort for AI development, the...

Daughter And Her Terminally Ill Dad Go On Bucket List Adventures In His Final Days

72-year-old Patrick Mitchell loves life and always wanted to live past 100, but everything changed when he found out that he had terminal stage...

A new year of expanding research horizons

As a new year of research gets underway, we ask two of our Research Committee Chairs to take stock of the incredible science done...

Young Women At Increased Risk Of Aggressive Breast Cancer

Breast cancer is on the rise among younger women. According to a study published in the Journal of the American Medical Association, there has been...